3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Solid Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Locally Advanced Solid Tumors
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
trastuzumab deruxtecan
4
eribulin
3
Capecitabine
3
Trastuzumab
2
Paclitaxel
2
Gemcitabine
2
Carboplatin
2
130-nm albumin-bound paclitaxel
2
telisotuzumab vedotin
1
taxane
1
pertuzumab
1
pembrolizumab
1
osimertinib
1
olaparib
1
margetuximab
1
exemestane
1
entrectinib
1
encorafenib
1
dacomitinib
1
capmatinib
1
binimetinib
1
adagrasib
1
abemaciclib
1
Vinorelbine
1
Vemurafenib
1
Pemetrexed
1
Imlunestrant
1
Gefitinib
1
Fulvestrant
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Neoplasm Metastasis
×
entrectinib
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA